$RARE News and Market Events
Every $RARE story Market Flux has tracked.
- Most Active
Ultragenyx Shares Plunge 44% After Angelman Syndrome Drug Fails Late-Stage Trial
Ultragenyx Pharmaceutical shares cratered roughly 44% on September 3, 2026, after its experimental treatment for Angelman syndrome, a rare neurodevelopmental genetic disorder, failed to…
- Market Flux Event
Ultragenyx Gets Accelerated FDA Approval for DTX401 Gene Therapy Targeting Rare Metabolic Disorder GSDIa
The U.S. Food and Drug Administration granted accelerated approval to Ultragenyx Pharmaceutical's gene therapy DTX401, known generically as pariglasgene brecaparvovec, for the treatment of…
- Market Flux Event
Estee Lauder Leads Wednesday Stock Movers as Earnings Beats and Deal News Drive Gains
Estee Lauder was the standout mover on Wednesday, with shares jumping more than 15% after the beauty conglomerate reported fiscal fourth-quarter revenue of $3.6 billion, up 6% year over…